AI designed cancer drug gets FDA approval for clinical trials
/in Artificial Intelligence, Not PCa related/by MaxThe Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/in Observational, Retrospective studies/by MaxNewsletter 2
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the second newsletter from the site. Last week, I had to travel for work, so I might have missed something! Let’s dive right in. We also have a podcast if you prefer to listen to the newsletter, you can […]
Nodularin-R Enhances Abiraterone’s Effectiveness Against Castration-Resistant Prostate Cancer In Vivo
/in Preclinical Research/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Phase 2 Trial: Optimal PSA-Triggered Intermittent Therapy for mHSPC October 15, 2025
- Self-Assembled Nano-PROTAC to Improve Targeted Therapy in Castration-Resistant Prostate Cancer October 15, 2025
- Dual Enzyme Blockade Weakens Prostate Cancer Tumors and Enhances Treatment Effectiveness October 15, 2025
- Phase 3 Trial: Xaluritamig (AMG 509) Plus Abiraterone in mCRPC October 13, 2025